MEDIPHARM LABS CORP. MEDIF overview

TORONTO, May 23, 2025 (GLOBE NEWSWIRE) -- MediPharm Labs Corp. (TSX: LABS) (“ MediPharm ”, the “ Company ”, or “ we ”), a pharmaceutical company specialized in precision-based cannabinoids, today provided its shareholders with information related to three of the six directors (the “ Dissident Nominees ”) nominated by Apollo Technology Capital Corporation (“ Apollo ”) to stand for election at MediPharm’s Annual and Special Meeting of Shareholders on June 16, 2025. All dollar...

TORONTO, May 22, 2025 (GLOBE NEWSWIRE) -- MediPharm Labs Corp. (TSX: LABS) (" MediPharm " or the " Company "), a pharmaceutical company specialized in precision-based cannabinoids, is pleased to announce the removal of all conditions precedent, related to its previously-announced agreement (the “ Purchase Agreement ”) for the sale of MediPharm’s facility in Hope, BC, (“ Hope Facility ”) to Rubicon Organics Inc. (TSXV: ROMJ ) (OTCQX: ROMJF) for $4.5 million in cash (the “ Transaction...

TORONTO, May 21, 2025 (GLOBE NEWSWIRE) -- MediPharm Labs Corp. (TSX: LABS) (" MediPharm " or the " Company "), a pharmaceutical company specialized in precision-based cannabinoids, today alerted its shareholders to publicly available information about Regan McGee, the controlling shareholder, director, Chairman and CEO of Apollo Technology Capital Corporation (“ Apollo ”), a dissident MediPharm shareholder. Apollo filed an amended and restated dissident proxy circular on May 20, 2025 (the...

TORONTO, Jan. 05, 2022 (GLOBE NEWSWIRE) -- MediPharm Labs Corp. (TSXV: LABS) (OTCQX: MEDIF) (FSE: MLZ) (“MediPharm Labs” or the “Company”) a pharmaceutical company specialized in precision-based cannabinoids, is pleased to announce that it has completed all payments required under its 2020 $41 million unsecured convertible debt. “MediPharm continues on its plan and path to profitability, and paying off our convertible debt in full is a major milestone on that path,” said Bryan...

MediPharm Labs pharma-quality CBD dominant oil line has been awarded CBD Brand of the year by KIND Magazine. MediPharm Labs’ CBD products have seen steady revenue growth and notoriety in 2021, including on national television on an episode of CBC Marketplace. BARRIE, Ontario, Dec. 22, 2021 (GLOBE NEWSWIRE) -- MediPharm Labs Corp . (TSX: LABS) (OTCQX: MEDIF) (FSE: MLZ) (“MediPharm Labs” or the “Company”) a pharmaceutical company specialized in precision-based cannabinoids, is pleased to...

Strong cash balance and continued reduction of convertible debt to less than $500K. Opportunities for optimization of the operating strategy between Australia and Canada as the Canadian Drug Establishment Licence (DEL) unlocks many manufacturing and supply chain pathways. These pathways will reduce infrastructure cost, improve delivery times, and increase customer satisfaction. Delivery to five international medical cannabis markets including first deliveries of advanced GMP CBD isolate to...

BARRIE, Ontario, Dec. 07, 2021 (GLOBE NEWSWIRE) -- MediPharm Labs Corp. (TSX: LABS) (OTCQX: MEDIF) (FSE: MLZ) (“MediPharm Labs” or the “Company”) a pharmaceutical company specialized in precision-based cannabinoids, is pleased to announce changes to its Board of Directors (the “Board”). Effectively immediately, Pat McCutcheon, Warren Everitt and Keith Strachan will be resigning from the Board. The change is being made as a next step in the Company’s transformation to an operating...

Patient based delivery of medical cannabis executed with approval from both Barbados and Canadian Health Authorities. This marks the fourth new country entered by MediPharm Labs in 2021, following initial shipments to Germany, Brazil and Peru. BARRIE, Ontario, Nov. 26, 2021 (GLOBE NEWSWIRE) -- MediPharm Labs Corp . (TSX: LABS) (OTCQX: MEDIF) (FSE: MLZ) (“MediPharm Labs” or the “Company”) a pharmaceutical company specialized in precision-based cannabinoids, is pleased to announce it has...